David Tuller has posted another wonderful article in his series on the PACE trial. In this article he asks the important question, Whatever happened to the FINE study?
The FINE study was published shortly before the PACE trial. (You can read the FINE study here.)
It used similar treatment strategies as well as a similar timeline as PACE, but unlike the PACE trial the authors concluded at the end of 70-week study that patients had not significantly benefited from "pragmatic care" (supportive listening, and gradually increasing activity).
Tuller's question is perfectly valid. Why does everyone cite the PACE trial, with its dubious claims of "recovery," while ignoring the FINE trial, which made no claims that patients had gotten better, let alone recovered?
Please feel free to express what you think of the PACE Trial.
You can send an email to the Lancet's editor, Richard Horton: richard.horton@lancet.com.
Refer to: "Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial" published by The Lancet, Volume 377, No. 9768, p 823–836, 5 March 2011. (You can read the full study here.)
You can sign a petition asking the Lancet to retract their publication of the PACE trial HERE.
Reprinted with the kind permission of David Tuller. This article first appeared on Dr. Vincent Racaniello's Virology Blog.
________________________________________________________
Trial By Error, Continued: Why has the PACE Study’s “Sister Trial” been “Disappeared” and Forgotten?
By David Tuller, DrPH, 9 NOVEMBER 2015
David Tuller is academic coordinator of the concurrent masters degree program in public health and journalism at the University of California, Berkeley.
In 2010, the BMJ published the results of the Fatigue Intervention by Nurses Evaluation, or FINE. The investigators for this companion trial to PACE, also funded by the Medical Research Council, reported no benefits to ME/CFS patients from the interventions tested.
In medical research, null findings often get ignored in favor or more exciting “positive” results. In this vein, the FINE trial seems to have vanished from the public discussion over the controversial findings from the PACE study. I thought it was important to re-focus some attention on this related effort to prove that “deconditioning” is the cause of the devastating symptoms of ME/CFS. (This piece is also too long but hopefully not quite as dense.)
An update on something else: I want to thank the public relations manager from Queen Mary University of London for clarifying his previous assertion that I did not seek comment from the PACE investigators before Virology Blog posted my story. In an e-mail, he explained that he did not mean to suggest that I hadn’t contacted them for interviews. He only meant, he wrote, that I hadn’t sent them my draft posts for comment before publication. He apologized for the misunderstanding.
I accept his apology, so that’s the end of the matter. In my return e-mail, however, I did let him know I was surprised at the expectation that I might have shared the draft with the PACE investigators before publication. I would not have done that whether or not they had granted me interviews. This is journalism, not peer-review. Different rules.
************************************************************************
In 2003, with much fanfare, the U.K. Medical Research Council
announced that it would fund two major studies of non-pharmacological treatments for chronic fatigue syndrome. In addition to PACE, the agency decided to back a second, smaller study called “Fatigue Intervention by Nurses Evaluation,” or FINE. Because the PACE trial was targeting patients well enough to attend sessions at a medical clinic, the complementary FINE study was designed to test treatments for more severely ill patients.
(Chronic fatigue syndrome is also known as myalgic encephalomyelitis, CFS/ME, and ME/CFS, which has now been adopted by U.S. government agencies. The British investigators of FINE and PACE prefer to call it chronic fatigue syndrome, or sometimes CFS/ME.)
Alison Wearden, a psychologist at the University of Manchester, was the lead FINE investigator. She also sat on the PACE Trial Steering Committee and wrote an article about FINE for one of the PACE trial’s participant newsletters. The Medical Research Council and the PACE team referred to FINE as PACE’s “sister” trial. The two studies included the same two primary outcome measures, self-reported fatigue and physical function, and used the same scales to assess them.
The FINE results were published in BMJ in April, 2010. Yet when
the first PACE results were published in The Lancet the following year, the investigators did not mention the FINE trial in the text. The trial has also been virtually ignored in the subsequent public debate over the results of the PACE trial and the effectiveness, or lack thereof, of the PACE approach.
What happened? Why has the FINE trial been “disappeared”?
*****
The main goal of the FINE trial was to test a treatment for homebound patients that adapted and combined elements of cognitive behavior therapy and graded exercise therapy, the two rehabilitative therapies being tested in PACE. The approach, called “pragmatic rehabilitation,” had been successfully tested in a small previous study. In FINE, the investigators planned to compare “pragmatic rehabilitation” with another intervention and with standard care from a general practitioner.
Here’s what the Medical Research Council
wrote about the main intervention in an article in its newsletter, MRC Network, in the summer of 2003: “Pragmatic rehabilitation…is delivered by specially trained nurses, who give patients a detailed physiological explanation of symptom patterns. This is followed by a treatment programme focussing on graded exercise, sleep and relaxation.”
The second intervention arm featured a treatment called “supportive listening,” a patient-centered and non-directive counseling approach. This treatment presumed that patients might improve if they felt that the therapist empathized with them, took their concerns seriously, and allowed them to find their own approach to addressing the illness.
The Medical Research Council committed 1.3 million pounds to the FINE trial. The study was conducted in northwest England, with 296 patients recruited from primary care. Each intervention took place over 18 weeks and consisted of ten sessions–five home visits lasting up to 90 minutes alternating with five telephone conversations of up to 30 minutes.
As in the PACE trial, patients were selected using
the Oxford criteria for chronic fatigue syndrome, defined as the presence of six months of medically unexplained fatigue, with no other symptoms required. The Oxford criteria have been widely criticized for yielding heterogeneous samples, and
a report commissioned by the National Institutes of Health this year recommended by the case definition be “retired” for that reason.
More specific case definitions for the illness require the presence of core symptoms like post-exertional malaise, cognitive problems and sleep disorders, rather than just fatigue per se. Because the symptom called post-exertional malaise means that patients can suffer severe relapses after minimal exertion, many patients and advocacy organizations consider increases in activity to be potentially dangerous.
To be eligible for the FINE trial, participants needed to score 70 or less out of 100 on the physical function scale, the
Medical Outcomes Study 36-Item Short Form Health Survey, known as the SF-36. They also needed to score a 4 or more out of 11 on the 11-item
Chalder Fatigue Scale, with each item scored as either 0 or 1. On the fatigue scale, a higher score indicated greater fatigue.
Among other measures, the trial also included a key objective outcome–the “time to take 20 steps, (or number of steps
taken, if this is not achieved) and maximum heart rate reached on a step-test.”
Participants were to be assessed on these measures at 20 weeks, which as right after the end of the treatment period, and again at 70 weeks, which was one year after the end of treatment. According to
the FINE trial protocol, published in the journal BMC Medicine in 2006, “short-term assessments of outcome in a chronic health condition such as CFS/ME can be misleading” and declared the 70-week assessment to be the “primary outcome point.”
*****
The theoretical model behind the FINE trial and pragmatic rehabilitation paralleled the PACE concept. The physical symptoms were presumed to be the result not of a pathological disease process but of “deconditioning” or “dysregulation” caused by sedentary behavior, accompanied by disrupted sleep cycles and stress. The sedentary behavior was itself presumed to be triggered by patients’ “unhelpful’ conviction that they suffered from a progressive medical illness. Counteracting the deconditioning involved re-establishing normal sleep cycles, reducing anxiety levels and gently increasing physical exertion, even if patients remained homebound.
“The treatment [pragmatic rehabilitation] is based on a model proposing that CFS/ME is best understood as a consequence of physiological dysregulation associated with inactivity and disturbance of sleep and circadian rhythms,” stated
the FINE trial protocol. “We have argued that these conditions…are often maintained by illness beliefs that lead to exercise-avoidance. The essential feature of the treatment is the provision of a detailed explanation for patients’ symptoms, couched in terms of the physiological dysregulation model, from which flows the rationale for a graded return to activity.”
On
the FINE trial website, a 2004 presentation about pragmatic rehabilitation
explained the illness in somewhat simpler terms, comparing it to “very severe jetlag.” After explaining how and why pragmatic rehabilitation led to physical improvement, the presentation offered this hopeful message, in boldface: “There is no disease–you have a right to full health. This is a good news diagnosis. Carefully built up exercise can reverse the condition. Go for 100% recovery.”
In contrast, patients, advcoates and many leading scientists have completely rejected the PACE and FINE approach. They believe the evidence overwhelmingly points to an immunological and neurological disorder triggered by an initial infection or some other physiological insult. Last month, the National Institutes of Health ratified this perspective when
it announced a major new push to seek biomedical answers to the disease, which it refers to as ME/CFS.
As in PACE, patients in the FINE trial were issued different treatment manuals depending upon their assigned study arm. The
treatment manual for pragmatic rehabilitation repeatedly informed participants that the therapy could help them get better—even though the trial itself was designed to test the effectiveness of the therapy. (In the PACE trial, the manuals for the cognitive behavior and graded therapy arms also included many statements promoting the idea that the therapies could successfully treat the illness.)
“This booklet has been written with the help of patients who have made a full recovery from Chronic Fatigue Syndrome,” stated the FINE pragmatic rehabilitation manual on its second page. “Facts and information which were important to them in making this recovery have been included.” The manual noted that the patients who helped write it had been treated at the Royal Liverpool University Hospital but did not include more specific details about their “full recovery” from the illness.
Among the “facts and information” included in the manual were assertions that the trial participants, contrary to what they might themselves believe, had no persistent viral infection and “no underlying serious disease.” The manual promised them that pragmatic rehabilitation could help them overcome the illness and the deconditioning perpetuating it. “Instead of CFS controlling you, you can start to regain control of your body and your life,” stated the manual.
Finally, as in PACE, participants were encouraged to change their beliefs about their condition by “building the right thoughts for your recovery.” Participants were warned that “unhelpful thoughts”—such as the idea that continued symptoms indicated the presence of an organic disease and could not be attributed to deconditioning—“can put you off parts of the treatment programme and so delay or prevent recovery.”
The supportive listening manual did not similarly promote the idea that “recovery” from the illness was possible. During the sessions, the manual explained, “The listener, your therapist, will provide support and encourage you to find ways to cope by using your own resources to change, manage or adapt to difficulties…She will not tell you what to do, advise, coach or direct you.”
*****
A qualitative study about the challenges of the FINE research process, published by the investigators in the journal Implementation Science in 2011, shed light on how much the theoretical framework and the treatment approaches frustrated and angered trial participants. According to the interviews with some of the nurses, nurse supervisors, and participants involved in FINE, the home visits often bristled with tension over the different perceptions of what caused the illness and which interventions could help.
“At times, this lack of agreement over the nature of the condition and lack of acceptance as to the rationale behind the treatment led to conflict,” noted the FINE investigators in the qualitative paper. “A particularly difficult challenge of interacting with patients for the nurses and their supervisors was managing patients’ resistance to the treatment.”
One participant in the pragmatic rehabilitation arm, who apparently found it difficult to do what was apparently expected, attributed this resistance to the insistence that deconditioning caused the symptoms and that activity would reverse them. “If all that was standing between me and recovery was the reconditioning I could work it out and do it, but what I have got is not just a reconditioning problem,” the participant said. “I have got something where there is damage and a complete lack of strength actually getting into the muscles and you can’t work with what you haven’t got in terms of energy.”
Another participant in the pragmatic rehabilitation arm was more blunt. “I kept arguing with her [the nurse administering the treatment] all the time because I didn’t agree with what she said,” said the participant, who ended up dropping out of the trial.
Some participants in the supportive listening arm also questioned the value of the treatment they were receiving, according to the study. “I mostly believe it was more physical than anything else, and I didn’t see how talking could truthfully, you know, if it was physical, do anything,” said one.
In fact, the theoretical orientation also alienated some prospective participants as well, according to interviews the investigators conducted with some patients who declined to enter the trial. ‘It [the PR intervention] insisted that physiologically there was nothing wrong,” said one such patient. “There was nothing wrong with my glands, there was nothing wrong, that it was just deconditioned muscles. And I didn’t believe that…I can’t get well with treatment you don’t believe in.”
When patients challenged or criticized the therapeutic interventions, the study found, nurses sometimes felt their authority and expertise to be under threat. “They are testing you all the time,” said one nurse. Another reported: “That anger…it’s very wearing and demoralizing.”
One nurse remembered the difficulties she faced with a particular participant. “I used to go there and she would totally block me, she would sit with her arms folded, total silence in the house,” said the nurse. “It was tortuous for both of us.”
At times, nurses themselves responded to these difficult interactions with bouts of anger directed at the participants, according to a supervisor.
“Their frustration has reached the point where they sort of boiled over,” said the supervisor. “There is sort of feeling that the patient should be grateful and follow your advice, and in actual fact, what happens is the patient is quite resistant and there is this thing like you know, ‘The bastards don’t want to get better.’”
*****
BMJ published
the FINE results in 2010. The FINE investigators found no statistically significant benefits to either pragmatic rehabilitation or supportive listening at 70 weeks. Despite these null findings one year after the end of the 18-week course of treatment, the mean scores of those in the pragmatic rehabilitative arm demonstrated at 20 weeks a “clinically modest” but statistically significant reduction in fatigue—a drop of one point (plus a little) on the 11-point fatigue scale. The slight improvement still meant that participants were much more fatigued than the initial entry threshold for disability, and any benefits were no longer statistically significant by the final assessment.
Despite the null findings at 70 weeks, the authors put a positive gloss on the results, reporting first in the abstract that fatigue was “significantly improved” at 20 weeks. Given the very modest one-point change in average fatigue scores, perhaps the FINE investigators intended to report instead that there was a “statistically significant improvement” at 20 weeks—an accurate phrase with a somewhat different meaning.
The abstract included another interesting linguistic element. While the trial protocol had designated the 70-week assessment as “the primary outcome point,” the abstract of the paper itself now stated that “the primary clinical outcomes were fatigue and physical functioning at the end of treatment (20 weeks) and 70 weeks from recruitment.”
After redefining their primary outcome points to include the 20-week as well as the 70-week assessment, the abstract promoted the positive effects found at the earlier point as the study’s main finding. Only after communicating the initial benefits did they note that these advantages for pragmatic rehabilitation later wore off. The FINE paper cited no oversight committee approval for this expanded interpretation of the trial’s primary outcome points to include the 20-week assessment, nor did it mention the protocol’s caveat about the “misleading” nature of short-term assessments in chronic health conditions.
In fact, within the text of the paper, the investigators noted that the “pre-designated outcome point” was 70 weeks. But they did not explain why they then decided to highlight most in the abstract what was not the pre-designated but instead a post-hoc “primary” outcome point—the 20-week assessment.
A BMJ editorial that accompanied the FINE trial also accentuated the positive results at 20 weeks rather than the bad news at 70 weeks. According to the editorial’s subhead, pragmatic rehabilitation “has a short term benefit, but supportive listening does not.” The editorial did not note that this was not the pre-designated primary outcome point. The null results for that outcome point—the 70-week assessment—were not mentioned until later in the editorial.
*****
Patients and advocates soon began criticizing the study in
the “rapid response” section of the BMJ website, citing its theoretical framework, the use of the broad Oxford criteria as a case definition, and the failure to provide the step-test outcomes, among other issues.
“The data provide strong evidence that the anxiety and deconditioning model of CFS/ME on which the trial is predicated is either wrong or, at best, incomplete,” wrote one patient. “These results are immensely important because they demonstrate that if a cure for CFS/ME is to be found, one must look beyond the psycho-behavioural paradigm.”
Another patient wrote that the study was “a wake-up call to the whole
of the medical establishment” to take the illness seriously. One predicted “that there will those who say that the this trial failed because
the patients were not trying hard enough.”
A physician from Australia sought to defend the interests not of patients but of the English language, decrying the lack of hyphens in the paper’s full title: “Nurse led, home based self help treatment for patients in primary care with chronic fatigue syndrome: randomised controlled trial.”
“The hyphen is a coupling
between carriages of words to ensure unambiguous
transmission of thought,” wrote the doctor. “Surely this should read ‘Nurse-led, home-based, self-
help…’
“Lest English sink further into the Great Despond of
ambiguity and non-sense [hyphen included in the original comment], may I implore the co-editors of
the BMJ to be the vigilant watchdogs of our mother tongue
which at the hands of a younger ‘texting’ generation is heading towards anarchy.” [The original comment did not include the expected comma between ‘tongue’ and ‘which.’]
*****
In
a response on the BMJ website a month after publishing the study, the FINE investigators reported that they had conducted a post-hoc analysis with a different kind of scoring for the Chalder Fatigue Scale.
Instead of scoring the answers as 0 or 1 using what was called a bimodal scale, they rescored them using what was called a continuous scale, with values ranging from 0 to 3. The full range of possible scores now ran from 0 to 33, rather than 0 to 11. (As collected, the data for the Chalder Fatigue Scale allowed for either scoring system; however, the original entry criteria of 4 on the bimodal scale would translate into a range from 4 to as high as 19 on the revised scale.)
With the revised scoring, they now reported a “clinically modest, but statistically significant effect” of pragmatic rehabilitation at 70 weeks—a reduction from baseline of about 2.5 points on the 0 to 33 scale. This final score represented some increase in fatigue from the 20-week interim assessment point.
In their comment on the website, the FINE investigators now reaffirmed that the 70-week assessment was “our primary outcome point.” This statement conformed to the protocol but differed from the suggestion in the BMJ paper that the 20-week results also represented “primary” outcomes. Given that the post-hoc rescoring allowed the investigators to report statistically significant results at the 70-week endpoint, this zig-zag back to the protocol language was perhaps not surprising.
In their comment, the FINE investigators also explained that they did not report their step-test results—their one objective measure of physical capacity–“due to a significant amount of missing data.” They did not provide an explanation for the missing data. (One obvious possible reason for missing data on an objective fitness test is that participants were too disabled to perform it at all.)
The FINE investigators did not address the question of whether the title of their paper should have included hyphens.
In the rapid comments, Tom Kindlon, a patient and advocate from a Dublin suburb,
responded to the FINE investigators’ decision to report their new post-hoc analysis of the fatigue scale. He noted that the investigators themselves had chosen the bimodal scoring system for their study rather than the continuous method.
“I’m
sure many pharmacological and non-pharmacological studies could look
different if investigators decided to use a different scoring method or
scale at the end, if the results weren’t as impressive as they’d hoped,” he wrote. “But that is not normally how medicine works. So, while it is interesting
that the researchers have shared this data, I think the data in the main
paper should be seen as the main data.”
*****
The FINE investigators have published a number of other papers arising from their study. In
a 2013 paper on mediators of the effects of pragmatic rehabilitation, they reported that there were no differences between the three groups on the objective measure of physical capacity, the step test, despite their earlier decision not to publish the data in the BMJ paper.
Wearden herself presented the trial as a high point of her professional career
in a 2013 interviewfor the website of the University of Manchester’s School of Psychological Sciences. “I suppose the thing I did that I’m most proud of is I ran a large treatment trial of pragmatic rehabilitation treatment for patients with chronic fatigue syndrome,” she said in the interview. “We successfully carried that trial out and found a treatment that improved patients’ fatigue, so that’s probably the thing that I’m most proud of.”
The interview did not mention that the improvement at 20 weeks was transient until the investigators performed a post-hoc-analysis and rescored the fatigue scale.
*****
The
Science Media Centre, a self-styled “independent” purveyor of information about science and scientific research to journalists, has consistently shown an interest in research on what it calls CFS/ME. It held a press briefing for the first PACE results published in The Lancet in 2011, and has helped publicize the release of subsequent studies from the PACE team.
However, the Science Media Centre does not appear to have done anything to publicize the 2010 release of the FINE trial, despite its interest in the topic. A search of the center’s website for the lead FINE investigator, Alison Wearden, yielded no results. And
a search for CFS/ME indicated that the first study embraced by the center’s publicity machine was the 2011 Lancet paper.
That might help explain why the FINE trial was virtually ignored by the media. A search on the LexisNexis database for “PACE trial” and “chronic fatigue syndrome” yielded 21 “newspaper” articles (I use the “apostrophes” here because I don’t know if that number includes articles on newspaper websites that did not appear in the print product; the accuracy of the number is also in question because the list did not include two PACE-related articles that I wrote for The New York Times).
Searches on the database combining “chronic fatigue syndrome” with either “FINE trial” or “pragmatic rehabilitation” yielded no results. (I used the version of LexisNexis Academic available to me through the University of California library system.)
Other researchers have also paid scant attention to the FINE trial, especially when compared to the PACE study. According to Google Scholar, the 2011 PACE paper in The Lancet has been cited 355 times. In contrast, the 2010 FINE paper in BMJ has only been cited 39 times.
*****
The PACE investigators likely exacerbated this virtual disappearance of the FINE trial by their decision not to mention it in their Lancet paper, despite its longstanding status as a “sister trial” and the relevance of the findings to their own study of cognitive behavior therapy and graded exercise therapy. The PACE investigators have not explained their reasons for ignoring the FINE trial. (I wrote about this lapse in my Virology Blog story, but in their response the PACE investigators did not mention it.)
This absence is particularly striking in light of the decision made by the PACE investigators to drop their protocol method of assessing the Chalder Fatigue Scale. In the protocol, their primary fatigue outcome was based on bimodal scoring on the 11-item fatigue scale. The protocol included continuous scoring on the fatigue scale, with the 0 to 33 scale, as a secondary outcome.
In the PACE paper itself, the investigators announced that they had dropped the bimodal scoring in favor of the continuous scoring “to more sensitively test our hypotheses of effectiveness.” They did not explain why they simply didn’t provide the findings under both scoring methods, since the data as collected allowed for both analyses. They also did not cite any references to support this mid-trial decision, nor did they explain what prompted it.
They certainly did not mention that PACE’s “sister” study, the FINE trial, had reported null results at the 70-week endpoint—that is, until the investigators rescored the data using a continuous scale rather than the bimodal scale used in the original paper.
The three main PACE investigators—psychiatrist Peter White and Michael Sharpe, and behavioral psychologist Trudie Chalder—did not respond to an e-mail request for comment on why their Lancet paper did not mention the FINE study, especially in reference to their post-hoc decision to change the method of scoring the fatigue scale. Lancet editor Richard Horton also did not respond to an e-mail request for an interview on whether he believed the Lancet paper should have included information about the FINE trial and its results.
